Mazen M Dimachkie

List of Publications by Year
in descending order

143	6,279	66343	82547
papers	citations	42 h-index	72 g-index

149	149	149	6499
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.9	754
2	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	5.6	391
3	Guillain-BarrÃ© Syndrome and Variants. Neurologic Clinics, 2013, 31, 491-510.	1.8	260
4	Clinical findings in MuSKâ€antibody positive myasthenia gravis: A U.S. experience. Muscle and Nerve, 2010, 41, 370-374.	2.2	216
5	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	10.2	194
6	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
7	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
8	Treatment of Myasthenia Gravis. Neurologic Clinics, 2018, 36, 311-337.	1.8	135
9	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 582.	9.0	126
10	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	3.8	115
11	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
12	Pompe Disease. Neurologic Clinics, 2014, 32, 751-776.	1.8	104
13	Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine, 2016, 8, 331ra41.	12.4	99
14	Human immunodeficiency virusâ€“associated polymyositis: A longitudinal study of outcome. Arthritis and Rheumatism, 2003, 49, 172-178.	6.7	97
15	Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. Journal of Immunology, 2017, 198, 1460-1473.	0.8	92
16	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
17	Long-Term Neurological Outcomes in West Nile Virusâ€“Infected Patients: An Observational Study. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1006-1012.	1.4	85
18	Nutritional Neuropathies. Neurologic Clinics, 2013, 31, 477-489.	1.8	83

#	Article	IF	Citations
19	Idiopathic Inflammatory Myopathies. Neurologic Clinics, 2014, 32, 595-628.	1.8	82
20	Diabetic Neuropathy Part 1. Neurologic Clinics, 2013, 31, 425-445.	1.8	81
21	Lambert-Eaton Myasthenic Syndrome. Neurologic Clinics, 2018, 36, 379-394.	1.8	80
22	Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 735-748.	1.8	78
23	Inclusion Body Myositis. Neurologic Clinics, 2014, 32, 629-646.	1.8	76
24	A Pattern Recognition Approach to Patients with a Suspected Myopathy. Neurologic Clinics, 2014, 32, 569-593.	1.8	70
25	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026.	10.2	59
26	Safety of Aerobic Exercise in People With Diabetic Peripheral Neuropathy: Single-Group Clinical Trial. Physical Therapy, 2015, 95, 223-234.	2.4	56
27	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	2.2	56
28	Inclusion Body Myositis. Current Neurology and Neuroscience Reports, 2013, 13, 321.	4.2	53
29	Chronic Inflammatory Demyelinating Polyneuropathy. Current Treatment Options in Neurology, 2013, 15, 350-366.	1.8	53
30	Primary Lateral Sclerosis. Neurologic Clinics, 2015, 33, 749-760.	1.8	53
31	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
32	Amifampridine phosphate (Firdapse^{Â®}) is effective and safe in a phase 3 clinical trial in LEMS. Muscle and Nerve, 2016, 53, 717-725.	2.2	51
33	Measuring Clinical Treatment Response in Myasthenia Gravis. Neurologic Clinics, 2018, 36, 339-353.	1.8	51
34	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
35	Very Late-Onset Friedreich Ataxia Despite Large GAA Triplet Repeat Expansions. Archives of Neurology, 2000, 57, 246.	4.5	50
36	Benefit of Qigong Exercise in Patients With Fibromyalgia: A Pilot Study. International Journal of Neuroscience, 2012, 122, 657-664.	1.6	50

#	Article	IF	Citations
37	Diagnosis of Myasthenia Gravis. Neurologic Clinics, 2018, 36, 261-274.	1.8	50
38	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
39	Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics, 2018, 15, 995-1005.	4.4	49
40	Ocular Myasthenia Gravis in an Academic Neuro-Ophthalmology Clinic: Clinical Features and Therapeutic Response. Journal of Clinical Neuromuscular Disease, 2011, 13, 46-52.	0.7	48
41	Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 889-908.	1.8	48
42	Idiopathic inflammatory myopathies. Journal of Neuroimmunology, 2011, 231, 32-42.	2.3	47
43	Clinical features of <scp>LRP4</scp>/agrinâ€antibodyâ€“positive myasthenia gravis: A multicenter study. Muscle and Nerve, 2020, 62, 333-343.	2.2	46
44	Autonomic nerve function in adult patients with cyclic vomiting syndrome. Neurogastroenterology and Motility, 2011, 23, 439-443.	3.0	44
45	Inclusion Body Myositis. Seminars in Neurology, 2012, 32, 237-245.	1.4	43
46	Toxic Myopathies. Neurologic Clinics, 2014, 32, 647-670.	1.8	42
47	Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2020, 61, 575-579.	2.2	41
48	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiology of Aging, 2016, 47, 218.e1-218.e9.	3.1	40
49	Multifocal Motor Neuropathy, Multifocal Acquired Demyelinating Sensory and Motor Neuropathy, and Other Chronic Acquired Demyelinating Polyneuropathy Variants. Neurologic Clinics, 2013, 31, 533-555.	1.8	39
50	Compromised fidelity of Bâ€cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	3.7	39
51	Idiopathic Inflammatory Myopathies. Seminars in Neurology, 2012, 32, 227-236.	1.4	37
52	Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid Î±-Glucosidase in Pompe Patients Co-administered with Alglucosidase Î±. Molecular Therapy, 2017, 25, 1199-1208.	8.2	36
53	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	36
54	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207.	2.2	35

#	Article	IF	Citations
55	Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (â€œProDERM Studyâ€). Medicine (United States), 2021, 100, e23677.	1.0	35
56	Reversible dementia and chorea in a young woman with the lupus anticoagulant. Neurology, 1996, 46, 1599-1603.	1.1	34
57	Distal Myopathies. Neurologic Clinics, 2014, 32, 817-842.	1.8	34
58	Congenital Myasthenic Syndromes: a Clinical and Treatment Approach. Current Treatment Options in Neurology, 2018, 20, 36.	1.8	34
59	cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Medical Science Monitor, 2004, 10, BR191-7.	1.1	32
60	Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.8	30
61	Toxic myopathies. Current Opinion in Neurology, 2018, 31, 575-582.	3.6	28
62	A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 345-352.	1.7	26
63	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. Neurology, 2021, 96, e1595-e1607.	1.1	25
64	Cryptogenic Sensory Polyneuropathy. Neurologic Clinics, 2013, 31, 463-476.	1.8	24
65	North America and South America (NA-SA) neuropathy project. International Journal of Neuroscience, 2013, 123, 563-567.	1.6	24
66	Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. Neurologic Clinics, 2018, 36, 293-310.	1.8	24
67	Peripheral nerve injury after brief lithotomy for transurethral collagen injection. Urology, 2000, 56, 669.	1.0	23
68	Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Statistics in Medicine, 2015, 34, 1134-1149.	1.6	23
69	A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics, 2015, 12, 455-460.	4.4	23
70	Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS). JAMA Neurology, 2021, 78, 68.	9.0	23
71	Diabetic Neuropathy Part 2. Neurologic Clinics, 2013, 31, 447-462.	1.8	22
72	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.1	22

#	Article	IF	Citations
73	A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization. Trials, 2016, 17, 428.	1.6	20
74	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
75	Sporadic inclusion body myositis. Current Opinion in Neurology, 2014, 27, 591-598.	3.6	18
76	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
77	Phenytoin-Induced Dermatomyositis: Case Report and Literature Review. Journal of Child Neurology, 1998, 13, 577-580.	1.4	16
78	A Review: The Use of Rituximab in Neuromuscular Diseases. Journal of Clinical Neuromuscular Disease, 2010, 12, 91-102.	0.7	16
79	Facial Onset Sensorimotor Neuronopathy Syndrome. Journal of Clinical Neuromuscular Disease, 2012, 14, 7-10.	0.7	16
80	The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiology of Aging, 2015, 36, 1766.e1-1766.e3.	3.1	16
81	Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. Neurology, 2022, 99, .	1.1	16
82	Identification of a Novel Mutation in Patients with Medium-Chain Acyl-CoA Dehydrogenase Deficiency. Molecular Genetics and Metabolism, 2000, 69, 259-262.	1.1	15
83	Idiopathic Inflammatory Myopathies. Frontiers of Neurology and Neuroscience, 2009, 26, 126-146.	2.8	15
84	Phase II trial of methotrexate in myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 23-28.	3.8	15
85	Quantifying Treatment-Related Fluctuations in CIDP. Neurology, 2021, 96, e1876-e1886.	1.1	15
86	Cauda equina syndrome as the isolated presentation of sarcoidosis. Journal of Neurology, 2000, 247, 573-574.	3.6	14
87	Guillain-BarrÃ© Syndrome. Current Treatment Options in Neurology, 2013, 15, 338-349.	1.8	14
88	Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 727-734.	1.8	14
89	Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents. Muscle and Nerve, 2020, 61, 17-25.	2.2	14
90	Critical Illness Polyneuropathy in Adolescence. Journal of Child Neurology, 1995, 10, 409-411.	1.4	13

#	Article	IF	Citations
91	Leg Amyotrophic Diplegia. Journal of Clinical Neuromuscular Disease, 2013, 15, 7-12.	0.7	13
92	An instrumented timed up and go in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2018, 57, 503-506.	2.2	13
93	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
94	Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. Neuromuscular Disorders, 2015, 25, 625-631.	0.6	12
95	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23.	1.7	12
96	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
97	Retrospective Chart Review of Duloxetine and Pregabalin in the Treatment of Painful Neuropathy. International Journal of Neuroscience, 2011, 121, 521-527.	1.6	11
98	Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors. European Neurology, 2021, 84, 43-48.	1.4	11
99	Peripheral Neuropathy Research Registry: A prospective cohort. Journal of the Peripheral Nervous System, 2019, 24, 39-47.	3.1	10
100	Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2020, 61, 644-649.	2.2	10
101	Exercise intolerance associated with a novel 8300t>C mutation in mitochondrial transfer RNAlys. Muscle and Nerve, 2006, 34, 437-443.	2.2	9
102	Correspondence Regarding: TDP-43 Proteinopathy and Motor Neuron Disease in Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29. Journal of Neuropathology and Experimental Neurology, 2011, 70, 96-97.	1.7	9
103	Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial. Physical Therapy, 2017, 97, 20-31.	2.4	9
104	Review process for IVIg treatment. Neurology: Clinical Practice, 2018, 8, 429-436.	1.6	9
105	Benign Monomelic Amyotrophy of the Lower Extremity. Journal of Clinical Neuromuscular Disease, 2000, 1, 181-185.	0.7	8
106	Acquired Immune Demyelinating Neuropathies. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 1241-1260.	0.8	8
107	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. Muscle and Nerve, 2019, 60, 161-168.	2.2	8
108	Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clinical and Experimental Rheumatology, 2022, 40, 384-393.	0.8	8

#	Article	IF	Citations
109	The Dilemma of the Clinical Trialist in Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 937-947.	1.8	7
110	Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2018, 20, 49-59.	0.7	7
111	Update on Inclusion Body Myositis. Current Rheumatology Reports, 2018, 20, 52.	4.7	7
112	Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part I: Traditional agents. Muscle and Nerve, 2020, 61, 5-16.	2.2	7
113	Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2021, 64, 243-254.	2.2	7
114	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
115	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
116	Approach to Muscle and Neuromuscular Junction Disorders. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 1536-1563.	0.8	6
117	Measuring change in inclusion body myositis: clinical assessments versus imaging. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	6
118	Is it really myositis? Mimics and pitfalls. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101764.	3.3	5
119	Less is More in Diabetic Neuropathy Diagnosis: Comparison of Quantitative Sudomotor Axon Reflex and Skin Biopsy. Journal of Clinical Neuromuscular Disease, 2017, 19, 5-11.	0.7	4
120	Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets. Journal of Visualized Experiments, 2020, , .	0.3	4
121	Blood-based Biomarkers for Amyotrophic Lateral Sclerosis. , 0, , 105-120.		4
122	Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective. Journal of Neuroscience Nursing, 2019, 51, 198-203.	1.1	3
123	Amyloid Myopathy as an Inclusion Body Myositis Mimic. RRNMF Neuromuscular Journal, 2020, 1, 28-32.	0.1	3
124	Abnormalities in the Autonomic Nerve Function Profile of Adults with Cyclic Vomiting Syndrome. American Journal of Gastroenterology, 2009, 104, S488.	0.4	3
125	<scp>Nonâ€dystrophic</scp> myotonia: 2â€year clinical and patient reported outcomes. Muscle and Nerve, 2022, 66, 148-158.	2.2	3
126	Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology, 2016, 87, 2067-2068.	1.1	2

#	Article	IF	Citations
127	Outcome measures in the idiopathic inflammatory myopathies. Neurology, 2017, 89, 20-21.	1.1	2
128	Myopathies. Neurologic Clinics, 2014, 32, xiii-xiv.	1.8	1
129	Peripheral Neuropathies. , 2015, , 857-888.		1
130	Rhabdomyolysis and COVID-19 Infection: Is It Due to Statin Use or Anti-TIF1-y Antibodies?. RRNMF Neuromuscular Journal, 2020, 1, 22-25.	0.1	1
131	Teaching NeuroImage: Immune Checkpoint Inhibitorâ€"Related Fasciitis and Myositis With Perifascicular Atrophy. Neurology, 2021, 97, 1049-1050.	1.1	1
132	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	1
133	Openâ€label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, , .	2.2	1
134	Preface. Neurologic Clinics, 2013, 31, xi-xii.	1.8	0
135	Motor Neuron Disease. Neurologic Clinics, 2015, 33, xiii-xiv.	1.8	0
136	Fifty Key Publications on Myasthenia Gravis and Related Disorders. Neurologic Clinics, 2018, 36, xiii-xvii.	1.8	0
137	NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism, 2019, 126, S115-S116.	1.1	0
138	Transthyretin Familial Amyloid Polyneuropathy Mimicking Chronic Inflammatory Demyelinating Polyneuropathy. RRNMF Neuromuscular Journal, 2020, 1, 26-31.	0.1	0
139	2269-PUB: Early Attrition from a Randomized Lifestyle Modification Protocol. Diabetes, 2019, 68, .	0.6	0
140	Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial. Kansas Journal of Medicine, 2020, 13, 10-13.	0.4	0
141	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	0
142	Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.. Clinical and Experimental Rheumatology, 2022, 40, 384-393.	0.8	0
143	Measuring change in inclusion body myositis: clinical assessments versus imaging.. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	0